JF
CBIO

Jump Financial’s Crescent Biopharma CBIO Stock Holding History

Jump Financial’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-115
Closed -$1.95K – 1791
2024
Q3 		$1.95K Buy
+115
New +$2.41K ﹤0.01% 1578
2024
Q2 		– Sell
-201
Closed -$60.3K – 1970
2024
Q1 		$60.3K Buy
+201
New +$60K ﹤0.01% 1824
2021
Q3 		– Sell
-180
Closed -$42K – 1236
2021
Q2 		$42K Buy
+180
New +$45.8K ﹤0.01% 1035
2021
Q1 		– Sell
-262
Closed -$99K – 1066
2020
Q4 		$99K Buy
+262
New +$91.8K 0.02% 869

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Jump Financial's CBIO Position: Q4 2024 in Review

Jump Financial sold out of Crescent Biopharma (CBIO) in Q4 2024, closing a stake of 115 shares — an estimated $1.95K sold.

Jump Financial first reported a position in CBIO in Q4 2020 and held it in 4 quarters. The position peaked at $99K in Q4 2020. 41 funds tracked by Wall St. Rank hold CBIO as of Q4 2024.

  • Jump Financial reported no remaining Crescent Biopharma position as of Q4 2024 after selling out during the quarter.
  • Jump Financial sold 115 Crescent Biopharma shares in Q4 2024, an estimated $1.95K.
  • Jump Financial first reported a position in Crescent Biopharma in Q4 2020 and held it in 4 quarters.
  • Jump Financial's Crescent Biopharma position peaked at $99K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2024.

Based on Jump Financial's 13F filing for Q4 2024, filed 13 Feb 2025.